Celiac Disease Treatment Market

Growing cases of celiac disease are driving the market growth

Market CAGR for celiac disease treatment is being driven by the rising cases of celiac diseases. The rise in the generality of diabetes in all age groups is increasing the case of celiac disease. Diabetes is a blood-glucose chronic disease because the body cannot produce the reacquired blood glucose. Increasing cases of diabetes have increased the concerns in government and healthcare organizations as these leads to the risk of celiac disease. The increase in these cases has increased the demand for the application of gluten-free products, thus growing the market.

Celiac disease is an illness that is autoimmune, in which the protein gluten hampers the membrane of the small intestine. Gluten is available in grains like rye, wheat, and barley. Consumption of gluten leads to an immunological reaction that hampers the villi of the small intestine, which is a small finger-like projection in the small intestine that promotes absorption. The capability of the body for absorbing nutrients, proteins, lipids, carbs, vitamins, and minerals is disturbed by the damage caused to villi in the small intestine, leading to malnutrition.

Celiac disease is a genetic auto-immune disorder that leads to many other diseases like low bone density, infertility, neurology, and certain cancers. There is no drug present on the market that can treat celiac disease; the symptoms include abdominal pain, low bone density, weight loss, and headache. If the symptoms are undiagnosed and not treated well can lead to neurological dysfunction, osteoporosis, anemia, and infertility.

The growing inclusion of therapeutic products in economically developed regions is fueling market growth. Also the growing favorable government policies throughout the Western world, rising clinical trials for drugs against celiac disease, and increase in consumption of foods like bread, pizza, and coke, which are high in gluten protein, lead to celiac diseases. The fast-tracking in restaurants offering ready-to-eat packaged foods, beverages addiction, junk food, altering lifestyle, and rising disposable income can increase the consumption of gluten protein. The technological advancement and rising modernization in the healthcare section and research & development activities will create new celiac disease treatment opportunities.

Thus, driving the Celiac Disease Treatment market revenue.

The constrained availability of the option of treatment in the market, the absence of specific drugs for the treatment of the disease, and most of the celiac disease cases remaining misdiagnosed are the main factors restraining the market growth of celiac disease treatment.

The Global Celiac Disease Treatment Market Industry is poised for substantial growth, with projections indicating a market value of 0.61 USD Billion in 2024 and an anticipated increase to 1.93 USD Billion by 2035. This growth is underpinned by a compound annual growth rate (CAGR) of 11.05% from 2025 to 2035. Such figures suggest a robust expansion driven by factors such as rising prevalence, advancements in treatment options, and increasing consumer awareness. The market's trajectory reflects a growing recognition of celiac disease and the need for effective management solutions, positioning it as a key area of focus for stakeholders in the healthcare sector.

Innovations in treatment options for celiac disease significantly influence the Global Celiac Disease Treatment Market Industry. Recent developments in gluten-free food technology and therapeutic interventions are enhancing the quality of life for patients. For instance, the introduction of enzyme-based therapies that aid in gluten digestion shows promise in clinical trials. These advancements not only provide alternatives to strict gluten avoidance but also expand the market landscape. As the industry evolves, the potential for new products to emerge is likely to attract investment and research, fostering a competitive environment that benefits patients and healthcare providers alike.

The growing awareness and education surrounding celiac disease are vital drivers for the Global Celiac Disease Treatment Market Industry. Healthcare professionals and organizations are increasingly focusing on educating the public about the symptoms and risks associated with celiac disease. Campaigns aimed at increasing knowledge about gluten intolerance and the importance of diagnosis are leading to more individuals seeking medical advice. This heightened awareness is expected to contribute to a steady increase in market demand, as more patients are diagnosed and treated. Consequently, the market is projected to grow at a CAGR of 11.05% from 2025 to 2035, reflecting the impact of education on treatment accessibility.

Regulatory support and guidelines play a crucial role in shaping the Global Celiac Disease Treatment Market Industry. Governments and health organizations are establishing frameworks to ensure the safety and efficacy of gluten-free products and treatments. For example, the FDA has set standards for gluten-free labeling, which helps consumers make informed choices. Such regulations not only enhance consumer confidence but also encourage manufacturers to innovate and comply with safety standards. This regulatory environment is likely to foster market growth, as companies are motivated to develop new products that meet these guidelines, ultimately benefiting patients and healthcare systems.

The increasing prevalence of celiac disease globally is a primary driver for the Global Celiac Disease Treatment Market Industry. As awareness of the condition grows, more individuals are being diagnosed, leading to a higher demand for effective treatment options. In 2024, the market is valued at 0.61 USD Billion, reflecting the urgent need for gluten-free products and therapies. This trend is expected to continue, with projections indicating that by 2035, the market could reach 1.93 USD Billion. The rising number of diagnosed cases emphasizes the necessity for innovative treatments and dietary solutions, thereby propelling market growth.

The surging demand for gluten-free products is a significant driver of the Global Celiac Disease Treatment Market Industry. As more consumers adopt gluten-free diets, whether due to celiac disease or other health concerns, the market for gluten-free foods and supplements is expanding rapidly. This trend is reflected in the increasing number of gluten-free product launches and the diversification of offerings in supermarkets and health food stores. The market's growth trajectory indicates that by 2035, it could potentially reach 1.93 USD Billion, driven by both celiac patients and health-conscious consumers seeking gluten-free alternatives.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Celiac Disease Treatment market dominates the celiac disease treatment market because of the increasing cases of celiac diseases, the availability of the major market players, and the growth in refined healthcare expenses in the North American region. The major contributor to celiac disease treatment is the US.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CELIAC DISEASE TREATMENT MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe's Celiac Disease Treatment market accounts for the second-largest market share because of the occurrence of market players and the rising government support for vaccine development. Further, the German Celiac Disease Treatment market held the largest market share, and the UK Celiac Disease Treatment market was the fastest-growing market in the European region.

The Asia-Pacific Celiac Disease Treatment Market is expected to grow at the rapid CAGR from 2023 to 2034. This is due to increasing awareness about the disease and increasing population in the region. Moreover, China’s Celiac Disease Treatment market held the largest market share, and the Indian Celiac Disease Treatment market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to spread their product lines, which will help the Celiac Disease Treatment market grow even more. Market participants are also undertaking a various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Celiac Disease Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Celiac Disease Treatment industry to benefit clients and increase the market sector. In recent years, the Celiac Disease Treatment industry has offered some of the most significant advantages to medicine. Major players in the Celiac Disease Treatment market, including General Mills Inc., Innovate Biopharmaceutical, ActoBio, Glenmark Pharmaceuticals Company Ltd., Takeda Pharmaceuticals Company Ltd., Zydus Pharmaceuticals Inc., BioLineRx, West-Ward Pharmaceuticals Company Ltd., Calypso Biotech SA, and others, are attempting to increase market demand by investing in R&D operations.

ActoBio, founded in 2006 and headquartered in Ghent, Belgium, is a biotechnological company at a clinical-stage developing a new class of therapeutic agents created on the ActoBiotics platform. The company targets microbe-based, mainly designed agents which can express and locally offer potential disease-modifying therapeutics at disease sites, including the intestine, the nasopharynx, and the mouth, to treat a range of disorders. The company invests largely in research and development to develop new and effective products.

In August 2019, ActoBio Therapeutics Inc., which is a fully owned subsidiary of Intrexon Corporation, announced that the US Food and the Drug Administration (FDA) has granted an Investigational New Drug (IND) application for the AG017, which is an orally-delivered drug for treating celiac disease.

Innovate Biopharmaceutical, founded in 2012, is a US-based clinical-stage company emphasizing creating novel gastroenterology medicines. Its drug portfolio consists of INN-202, a tight junction regulator that assists in restoring open junction to a normal state and is in phase 3 trials for Celiac Disease (CeD), and INN-108, which is a small molecule in phase 2 trials for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan diseases. INN-108 is a pro-drug that is activated only colon, and the convenience of liquid is important for children and the aging population.

In August 2019, Innovative Biopharmaceuticals Inc. announced the first patient enrollment in its Phase III clinical trial, CeD LA 3001, for Larazotide acetate, a drug candidate for treating celiac disease.